MORE safety concerns with dronedarone (Multaq)

October 2011

See the December 2011 completed FDA safety review of Multaq (dronedarone)

There are MORE safety concerns with dronedarone (Multaq).

This time it has to do with the TYPE of atrial fibrillation.

Multaq improves CV outcomes in some patients with PAROXYSMAL or PERSISTENT atrial fib. These resolve spontaneously or with cardioversion.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Anticoagulants controversy over which ORAL anticoagulant to use to prevent strokes in patients with atrial fibrillation
Diabetes Trajenta (TRA-gen-ta), a new gliptin for type 2 diabetes
Diabetes using A1C to DIAGNOSE type 2 diabetes
Antidepressants limiting doses of citalopram (Celexa, etc)
Antidepressants Does folic acid improve the efficacy of antidepressants
Respiratory & Allergy chronic azithromycin to PREVENT recurrent COPD exacerbations
Women's Health tighter and more aggressive control of hypothyroidism before and during pregnancy
Corticosteroids whether hyperglycemia can occur with non-oral corticosteroids
Lupus new IV monoclonal antibody for severe systemic lupus erythematosus (SLE), Benlysta (ben-LIST-a, belimumab)
Geriatrics manage elderly dementia patients who have behaviour issues
Cardiology MORE safety concerns with dronedarone (Multaq)
Interactions Computer alerts about an interaction between potassium chloride tabs or caps and anticholinergics are causing confusion